GLP-1 drugs on FDA’s drug shortage list: a dated timeline
FDA added Wegovy (semaglutide) to its drug shortage list on March 31, 2022, Ozempic on August 23, 2022 and tirzepatide injection on December 15, 2022. It declared the tirzepatide shortage resolved on October 2, 2024 and again, after a court remand, on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025. As of Nov 15, 2026, FDA’s shortage data, read through openFDA, lists no semaglutide and no tirzepatide presentations with status “Current,” and 9 liraglutide presentations with that status.
Each quoted line below is FDA’s own wording, re-checked against the source on every weekly update; all were found at the last check. Lines without quotation marks come from FDA’s shortage data itself.
| FDA’s words or record | Source | |||
|---|---|---|---|---|
| Mar 31, 2022 | Semaglutide | Listed | “Wegovy was approved by FDA in June 2021 (NDA 215256) and added to FDA’s drug shortage list on March 31, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Aug 23, 2022 | Semaglutide | Listed | “Ozempic was approved by FDA in December 2017 (NDA 209637) and added to FDA’s drug shortage list on August 23, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Dec 15, 2022 | Tirzepatide | Listed | “Tirzepatide injection products were first added to FDA’s drug shortage list on December 15, 2022.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Jul 18, 2023 | Liraglutide | Listed | FDA’s shortage data posts Liraglutide Injection (Liraglutide, Victoza, Saxenda) with status “Current,” first posted Jul 18, 2023: 9 presentations. | FDA drug shortage data, via openFDA drug shortages endpoint |
| April 2024 | Tirzepatide | Listed | “The Zepbound pen products were approved by FDA in November 2023 (NDA 217806) and added to FDA’s drug shortage list in April 2024 due to high demand.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Oct 2, 2024 | Tirzepatide | Resolved | “The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Oct 22, 2024 | Tirzepatide | Litigation | “As part of litigation, the decision to remove tirzepatide from the FDA drug shortage list has been remanded to the agency for reevaluation.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Dec 19, 2024 | Tirzepatide | Resolved | “This order revokes and replaces FDA’s October 2, 2024 decision on the same subject. I. Determination FDA determines that the tirzepatide injection product shortage is resolved.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Feb 18, 2025 | Tirzepatide | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until February 18, 2025” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Feb 21, 2025 | Liraglutide | Status statement | “Liraglutide injection : In shortage. Manufacturer has reported two presentations are available, and three have limited availability.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Feb 21, 2025 | Semaglutide | Resolved | “FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Mar 5, 2025 | Tirzepatide | Litigation | “On March 5, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.).” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Mar 19, 2025 | Tirzepatide | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until March 19, 2025.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Apr 22, 2025 | Semaglutide | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until April 22, 2025” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 24, 2025 | Semaglutide | Litigation | “On April 24, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) regarding compounded semaglutide.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 22, 2025 | Semaglutide | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until May 22, 2025.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 1, 2026 | Semaglutide | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Apr 1, 2026 | Tirzepatide | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 14, 2026 | Liraglutide | To Be Discontinued | FDA’s shortage data posts Liraglutide Injection (Liraglutide) with status “To Be Discontinued,” first posted May 14, 2026: 1 presentation. | FDA drug shortage data, via openFDA drug shortages endpoint |
| Jun 4, 2026 | Semaglutide | To Be Discontinued | FDA’s shortage data posts Semaglutide Tablet (Rybelsus) with status “To Be Discontinued,” first posted Jun 4, 2026: 3 presentations. | FDA drug shortage data, via openFDA drug shortages endpoint |
| Aug 25, 2026 | Liraglutide | To Be Discontinued | FDA’s shortage data posts Liraglutide Injection (Saxenda) with status “To Be Discontinued,” first posted Aug 25, 2026: 1 presentation. | FDA drug shortage data, via openFDA drug shortages endpoint |
Compounding grace periods FDA set when the shortages ended
When a drug leaves the shortage list, compounders lose the shortage basis for making copies of it. In each order FDA said it would not act, for a set time, on violations that depend on the drug’s presence on the shortage list.
| Drug | Shortage resolved | 503A pharmacies and physicians: until | 503B outsourcing facilities: until | Source |
|---|---|---|---|---|
| Tirzepatide injection | December 19, 2024 | February 18, 2025 | March 19, 2025 | FDA order, Dec 19, 2024 |
| Semaglutide injection | February 21, 2025 | April 22, 2025 | May 22, 2025 | FDA order, Feb 21, 2025 |
FDA’s statement page adds that the 503A periods could run until a pending court ruling if that came later. Courts denied the preliminary injunctions on March 5, 2025 (tirzepatide) and April 24, 2025 (semaglutide), and FDA then stated the 503A periods had ended and the 503B periods ran to the dates above.
Current entries in FDA’s shortage data
FDA’s Drug Shortages Database pages, read Nov 15, 2026 as a second check: Semaglutide Injection, “Resolved”; Tirzepatide Injection, “Resolved”; Liraglutide Injection, “Currently in Shortage”. Per-presentation entries are on each drug page: semaglutide, tirzepatide, liraglutide.
Answer pages: Is semaglutide still on the FDA shortage list? and Is tirzepatide still on the FDA shortage list?
Common questions
What does “Resolved” mean on FDA’s shortage list?
FDA’s Drug Shortages Staff gives a drug Resolved status when it determines the market is covered: supply is available from at least one manufacturer to cover total demand, though some presentations may still be unavailable.
What does “To Be Discontinued” mean?
It is FDA’s notice that a manufacturer plans to stop making a presentation. It is listed with shortage data but is not a shortage determination.
Sources
- FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy)
- FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA drug shortage data, via openFDA drug shortages endpoint
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Drug Shortages Database: Semaglutide Injection
- FDA Drug Shortages Database: Tirzepatide Injection
- FDA Drug Shortages Database: Liraglutide Injection
Records last pulled Nov 15, 2026. Every entry links to the original public record.